FrançaisAre analysts right about Johnson & Johnson (JNJ)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Johnson & Johnson, we replayed every analyst price target of the past 12 months and measured the real outcome: 24% were profitable, average return +10% (179 calls). At 3 months: +2% average return (33% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Cantor Fitzgerald | 40 | 5% | +4% |
| RBC Capital | 23 | 39% | +19% |
| Raymond James | 23 | 13% | +8% |
| Citigroup | 17 | 35% | +12% |
| Credit Suisse | 16 | 6% | +4% |
Valuation
Is Johnson & Johnson overvalued, and is it a good time to buy Johnson & Johnson right now? If you're wondering, here's a recap to make up your own mind: Johnson & Johnson's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price ÷ earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects — but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Johnson & Johnson | Sector median (Health Care) |
|---|---|---|
| P/E | 30.9 | 29.4 |
| Forward P/E | 21.6 | 17.1 |
| Net margin | 21% | 12% |
👉 Johnson & Johnson is valued in line with its sector (30.9 vs 29.4).
📖 P/E, PEG, margin…: see the glossary
💵 Dividend : Johnson & Johnson pays about $5.24/share/yr → 2.06% yield. what is this?
Frequently asked questions
Is Johnson & Johnson a buy right now?
The analyst consensus on Johnson & Johnson (JNJ) is "Buy" (36 bullish, 0 bearish calls over 12 months). This is not advice: historically, 24% of their targets on this stock turned out profitable over 1 year.
What is Johnson & Johnson's price target?
The median 12-month price target is $280 (+5% vs $266), ranging from $250 to $300 (13 analysts).
Are analysts accurate on Johnson & Johnson?
Over 1 year, 24% of analyst targets on Johnson & Johnson were profitable, for an average return of +10% (across 179 timestamped calls). This is JPI Invest's accuracy metric.
What is the Johnson & Johnson stock forecast?
Analysts target a median of $280 within 12 months, i.e. +5% vs the current price. The most bullish targets $300, the most cautious $250.
What is the Johnson & Johnson stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $280, +5%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (24%), and the stock's past trajectory.
Is Johnson & Johnson overvalued?
Its P/E is 30.9, forward P/E 21.6. A forward P/E lower than the current P/E means earnings are expected to grow.
📊 See the full interactive analysis of Johnson & Johnson →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.